Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
about
Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infectionMonoclonal CCR5 antibody for treatment of people with HIV infectionCCR5 antagonism in HIV infection: current concepts and future opportunitiesClosing the door to human immunodeficiency virus.Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseasesCCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAARTThe isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIVThe critical need for alternative antiretroviral formulations, and obstacles to their development.CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaquesDiscovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.Gene Expression Profiling of Tuberculous Meningitis Co-infected with HIVHost Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic ApproachesA vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251.Recent advances in antiretroviral drugs.Immunotherapeutic restoration in HIV-infected individuals.Pharmacological modulation of chemokine receptor function.Candidate antibody-based therapeutics against HIV-1.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and preventionUniversal antiretroviral regimens: thinking beyond one-pill-once-a-day.The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.Parenteral antiretroviral formulations are still urgently needed: a case report and commentary.IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.New Drugs in the Pipeline for the Treatment of HIV: a Review.Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy.HIV Entry and Its Inhibition by Bifunctional Antiviral ProteinsGenetic Strategies for HIV Treatment and Prevention
P2860
Q24194805-32FAEF9C-212D-49AC-A082-8E02FBD4094DQ24235689-EB6D1826-A7AA-4964-B05E-757DF18F7528Q26865457-B69FAFFB-C9B4-4F18-9F91-92AB68FC617DQ30428089-A2E5B3C7-7BF7-46BE-BF3B-3D1DBB76B24CQ33887352-5B2D5BFB-16BE-470A-87D8-18713A069222Q34150882-8595693B-E2B2-4DB5-AB08-B960776295EFQ34536782-0F495BF1-D9CF-468E-8860-7031A7DC31A3Q34574397-7C26C10B-C324-45FA-B3B4-7BCC3C0CB8C7Q34647798-B9DA0E98-7C1A-4B57-9751-DA57DFE086ACQ34939533-1A0B7228-0C0B-45A5-8B55-757623503C7BQ35164438-BC650923-181A-4928-903B-D99E03015B1FQ35693333-C8180BDA-1733-4EC1-9DE0-4B6194F3580BQ36393594-094729BE-D86E-402B-9D9C-63B02E241261Q36763801-C4FAEE9E-E5D6-4946-8D06-46C15D665710Q37252004-AA127D2A-2653-4C9C-9876-9671469A548FQ37547093-38F9EB34-5F3C-46D1-A68E-EF5ACCB0A023Q37779092-C79673E4-06A7-4A42-8D1A-9D8C85D849B0Q37842335-452D39B8-A5FC-4714-8096-5EC999B163E5Q37893687-0139BC9D-87A6-4FFB-8751-EDB2B8117D24Q37998496-17C0B2A9-0F7D-4D17-9A3B-54B120FFB14FQ38196457-72F5AB03-4F03-471A-9E91-9763E6081A9DQ38574172-49E4BACE-A261-48B5-80B8-817FD0B264B6Q38717198-CD5A529B-0F37-480B-82AE-89F038C1827CQ39161979-D369293E-F7A4-45E9-996F-F02D1CA301B9Q39215169-B21D3A92-61BF-4563-8C75-ACD941A624FBQ39330860-A65F6DD6-7673-4106-9E15-E85CE9168422Q39433833-3ABF7499-8BB0-4A2F-8898-F3C9260CAB3BQ39435224-BA4FECC7-2BC7-4CCB-94DF-AE94E0F06C13Q42212544-A47EF826-BC66-40E0-95FE-2D01434DA3A1Q42732010-141E921C-16A4-4FA9-A96C-B3651F0FAE26Q45067800-B5473536-25B0-41B7-A179-9B91D3BFCE83Q47174470-840DC57C-568C-4343-AB08-DA8500F11020Q48256010-0CF8C116-857C-482F-958E-10C2106EB160Q58555325-7BBA4998-F25E-42EF-9A6C-2ECB097BD0F7Q58604627-1A8CBBFA-0DD6-4B60-9EFA-E02EC149408A
P2860
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.
@ast
Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.
@en
type
label
Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.
@ast
Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.
@en
prefLabel
Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.
@ast
Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.
@en
P2093
P2860
P356
P1476
Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.
@en
P2093
Andre J Marozsan
Barry S Zingman
Jacob P Lalezari
Jeffrey M Jacobson
Melanie A Thompson
Michael S Saag
Nancy Stambler
Paul D'Ambrosio
Paul J Maddon
Stephen A Morris
P2860
P304
P356
10.1086/652190
P407
P577
2010-05-01T00:00:00Z